STK33 kinase activity is nonessential in KRAS-dependent cancer cells

Cancer Research

Volumn 71, Issue 17, 2011, Pages 5818-5826

  Babij, Carol ^a   Zhang, Yihong ^a   Kurzeja, Robert J ^a   Munzli, Anke ^a   Shehabeldin, Amro ^a   Fernando, Manory ^a   Quon, Kim ^a   Kassner, Paul D ^a   Ruefli Brasse, Astrid A ^a   Watson, Vivienne J ^a   Fajardo, Flordeliza ^a   Jackson, Angela ^a   Zondlo, James ^a   Sun, Yu ^a   Ellison, Aaron R ^a   Plewa, Cherylene A ^a   Miguel, Tisha San ^a   Robinson, John ^a   McCarter, John ^a   Schwandner, Ralf ^a   Judd, Ted ^a   Carnahan, Josette ^a   Dussault, Isabelle ^a   more..

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; STK3 KINASE; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA INTERFERENCE;

EID: 80052187354     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0778     Document Type: Article

References (15)

1. Sebolt-Leopold JS. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res 2008;14:3651-6.
2. Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta 2005;1756:127-44.
3. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009;137:821-34.
4. Mujica AO, Hankeln T, Schmidt ER. A novel serine/threonine kinase gene,STK33,onhumanchromosome11p15.3.Gene2001;280:175-81.
5. Brauksiepe B, Mujica AO, Herrmann H, Schmidt ER. The Serine/threonine kinase Stk33 exhibits autophosphorylation and phosphorylates the intermediate filament protein Vimentin. BMC Biochem 2008;9:25.
6. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80. (Pubitemid 34879334)
7. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase inthe blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42. (Pubitemid 32267973)
8. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
9. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
10. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med .363:809-19.
11. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009;462:108-12.
12. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009;137:835-48.
13. Grueneberg DA, Degot S, Pearlberg J, Li W, Davies JE, Baldwin A, et al. Kinase requirements in human cells: I. Comparing kinase requirements across various cell types. Proc Natl Acad Sci U S A 2008;105:16472-7.
14. Echeverri CJ, Beachy PA, Baum B, Boutros M, Buchholz F, Chanda SK, et al. Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods 2006;3:777-9. (Pubitemid 44445821)
15. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68:8022-30. Sanger.ac.uk [homepage on the Internet]: Wellcome Trust Sanger Institute; [cited Mar 23, 2011]. Available from:http://www.sanger.ac.uk/ genetics/CGP.